Clearstead Advisors, LLC Adc Therapeutics Sa Transaction History
Clearstead Advisors, LLC
- $7.4 Billion
- Q3 2025
A detailed history of Clearstead Advisors, LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Clearstead Advisors, LLC holds 1 shares of ADCT stock, worth $4. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1Holding current value
$4% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ADCT
# of Institutions
93Shares Held
67.8MCall Options Held
68.2KPut Options Held
75.8K-
Redmile Group, LLC San Francisco, CA15.7MShares$66 Million5.11% of portfolio
-
Prosight Management, LP Dallas, TX10.5MShares$44.1 Million7.6% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct7.76MShares$32.7 Million0.05% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.91MShares$24.9 Million0.57% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$15 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $327M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...